ART-TG – Technology Research Accelerator in Genomic Therapy
ART-TG – Technology Research Accelerator in Genomic Therapy
Description
Therapeutic areas of interest are immunotherapy (cancer or infectious diseases), gene therapy of genetic diseases of the blood or immune system, two fields with high innovation potential and need for genomic therapy developments.
The Technologyl Research Accelerator in Genomic Therapy (ART-TG) is an innovation center that was established to promote excellence in gene therapy research.
ART-TG is a pre-GMP stage R&D laboratory aiming to bridge a gap between research and clinical or industrial applications. It has pharmaceutical expertise for product development and product manufacturing, specifically for genomic therapy approaches.
ART-TG provides an R&D platform allowing on the one hand to develop products for clinical applications, and on the other hand to set up the manufacturing processes and control of gene therapy products. Focusing more specifically on immunotherapy and hematology, ART-TG provides technological, preclinical and pharmaceutical skills. ART-TG works on improving the bioproduction processes of lentiviral vectors. ART-TG is also developing innovative approaches for the immunotherapy of infectious diseases or for the treatment of genetic diseases such as sickle cell anemia. The ART-TG is located south of Paris at the Genopole biocluster in Evry which supports its activities.
The Technologyl Research Accelerator in Genomic Therapy (ART-TG) is an innovation center that was established to promote excellence in gene therapy research.
ART-TG is a pre-GMP stage R&D laboratory aiming to bridge a gap between research and clinical or industrial applications. It has pharmaceutical expertise for product development and product manufacturing, specifically for genomic therapy approaches.
ART-TG provides an R&D platform allowing on the one hand to develop products for clinical applications, and on the other hand to set up the manufacturing processes and control of gene therapy products. Focusing more specifically on immunotherapy and hematology, ART-TG provides technological, preclinical and pharmaceutical skills. ART-TG works on improving the bioproduction processes of lentiviral vectors. ART-TG is also developing innovative approaches for the immunotherapy of infectious diseases or for the treatment of genetic diseases such as sickle cell anemia. The ART-TG is located south of Paris at the Genopole biocluster in Evry which supports its activities.
Referent Contact
Galy Anne
Director
ART-TG – Technology Research Accelerator in Genomic Therapy
Address
30 rue Henri Desbruères
91100 Corbeil-essonnes, France
91100 Corbeil-essonnes, France
Contact
art-tg@inserm.fr
Description
Therapeutic areas of interest are immunotherapy (cancer or infectious diseases), gene therapy of genetic diseases of the blood or immune system, two fields with high innovation potential and need for genomic therapy developments.
The Technologyl Research Accelerator in Genomic Therapy (ART-TG) is an innovation center that was established to promote excellence in gene therapy research.
ART-TG is a pre-GMP stage R&D laboratory aiming to bridge a gap between research and clinical or industrial applications. It has pharmaceutical expertise for product development and product manufacturing, specifically for genomic therapy approaches.
ART-TG provides an R&D platform allowing on the one hand to develop products for clinical applications, and on the other hand to set up the manufacturing processes and control of gene therapy products. Focusing more specifically on immunotherapy and hematology, ART-TG provides technological, preclinical and pharmaceutical skills. ART-TG works on improving the bioproduction processes of lentiviral vectors. ART-TG is also developing innovative approaches for the immunotherapy of infectious diseases or for the treatment of genetic diseases such as sickle cell anemia. The ART-TG is located south of Paris at the Genopole biocluster in Evry which supports its activities.
The Technologyl Research Accelerator in Genomic Therapy (ART-TG) is an innovation center that was established to promote excellence in gene therapy research.
ART-TG is a pre-GMP stage R&D laboratory aiming to bridge a gap between research and clinical or industrial applications. It has pharmaceutical expertise for product development and product manufacturing, specifically for genomic therapy approaches.
ART-TG provides an R&D platform allowing on the one hand to develop products for clinical applications, and on the other hand to set up the manufacturing processes and control of gene therapy products. Focusing more specifically on immunotherapy and hematology, ART-TG provides technological, preclinical and pharmaceutical skills. ART-TG works on improving the bioproduction processes of lentiviral vectors. ART-TG is also developing innovative approaches for the immunotherapy of infectious diseases or for the treatment of genetic diseases such as sickle cell anemia. The ART-TG is located south of Paris at the Genopole biocluster in Evry which supports its activities.
Matchmaking
Connect with ART-TG – Technology Research Accelerator in Genomic Therapy
This entity is yours?
Update informationPosition on the value chain
With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.
Bio-resources and biobanking
- Cells, tissues and humanized xeno-organs
- Biosamples
- Viral, phage or bacterial specimen
Identification of biotherapies
- Target identification
- Target validation
- Screening
Drug design
- Drug assessment
- Drug engineering
- In vitro preclinical studies
Clinical validation
- Clinical trials
- In vivo preclinical validation
- Pre-industrial scale production
Production
- Upstream processes
- Downstream processes
- Quality control
Market access
- CE mark / market authorisation
- Payment / Reimbursement
- Care pathways
Partnership needs
-
Regulatory aspects
-
Research & Development
-
Education & Training